Last updated on March 2020

Natural Killer Cell (CYNK-001) Infusions in Adults With AML


Brief description of study

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

Clinical Study Identifier: NCT04310592

Find a site near you

Start Over

Tennessee Oncology

Nashville, TN United States
  Connect »